Home / Yunxing Polystictus Glycopeptide Capsules or YunZhi BaoNei TangTai JiaoNang For the adjuvant treatment of chronic hepatitis B, liver cancer and elderly immunocompromised persons.
  • Yunxing Polystictus Glycopeptide Capsules or YunZhi BaoNei TangTai JiaoNang   For the adjuvant treatment of chronic hepatitis B, liver cancer and elderly immunocompromised persons.
  • Yunxing Polystictus Glycopeptide Capsules or YunZhi BaoNei TangTai JiaoNang   For the adjuvant treatment of chronic hepatitis B, liver cancer and elderly immunocompromised persons.
  • Yunxing Polystictus Glycopeptide Capsules or YunZhi BaoNei TangTai JiaoNang   For the adjuvant treatment of chronic hepatitis B, liver cancer and elderly immunocompromised persons.
  • Yunxing Polystictus Glycopeptide Capsules or YunZhi BaoNei TangTai JiaoNang   For the adjuvant treatment of chronic hepatitis B, liver cancer and elderly immunocompromised persons.
  • Yunxing Polystictus Glycopeptide Capsules or YunZhi BaoNei TangTai JiaoNang   For the adjuvant treatment of chronic hepatitis B, liver cancer and elderly immunocompromised persons.

Yunxing Polystictus Glycopeptide Capsules or YunZhi BaoNei TangTai JiaoNang For the adjuvant treatment of chronic hepatitis B, liver cancer and elderly immunocompromised persons.

Quantity
ADD TO CART
BUY IT NOW
Detail
Customer Reviews

云芝胞内糖肽胶囊

Generic name: Yunzhi intracellular glycopeptide capsules
Chinese Pinyin: YunXingYunZhiBaoNeiTangTaiJiaoNang
English name: Polystictus Glycopeptide Capsules
Product name: Yunxing
Ingredients: The ingredient of this product is Yunzhi intracellular glycopeptide.
Properties: This product is a capsule, and its content is brown or reddish brown powder or granules.
Indications: For the adjuvant treatment of chronic hepatitis B, liver cancer and elderly immunocompromised persons.
Specification: 0.5g*30 capsules/box
Usage and dosage: Oral. 0.5~1.0g once, 3 times a day.
Taboo: People who are allergic to this product should not be used.
Note: 1 Use with caution or follow the doctor's advice for urinary patients.
2 It is forbidden to use the drug when its properties change.
Pharmacology and Toxicology: 1 This product can enhance the function of reticuloendothelial system (RES) by enhancing the proliferation of monocytes and macrophages and activating the function of each phagocyte. It can significantly increase the concentration of serum interferon in mice; it can increase the phagocytic activity of neutrophils by activating the function of white blood cells without increasing the number of white blood cells; it can promote a single immunization of SRBC in 615 mice The production of specific hemolysin antibody; it can antagonize the strong suppression of cellular immunity caused by cyclophosphamide, methotrexate, 5-FU, mitomycin C, etc., improve cellular immunity and return to normal. 2 For acute liver injury in rats and mice caused by D-galactosamine and carbon tetrachloride, this product can significantly inhibit the increase of SGP, and the occurrence rate of hepatocyte steatosis is lower than that of the control group, and can be completely avoided The appearance of focal necrosis. 3 This product can make mouse peritoneal macrophages kill Ehrlich ascites cancer cells by 41% to 54%; it can enhance the effect of anticancer drugs; this product can also reduce the level of growth factor TGF-β1, Effectively inhibit tumor angiogenesis and the growth of transplanted breast cancer. 4 This product can strongly activate the body's own defense immune system, has secondary non-specific anti-infection and anti-shock effects, and can significantly reduce the mortality rate caused by Staphylococcus aureus, Escherichia coli, and Shigella infections. For influenza virus This product also has a significant protective effect on the death of mice caused by infection, with a protection rate of 50% to 60%, and the average survival time can be extended by 153% to 188%.
Storage: Keep tightly closed in a cool and dry place.
Packing: 0.5g*30 capsules/box.
Validity period: 24 months
Approval number: National Medicine Standard H50020929
Company Name: Peking University International Hospital Group Chongqing Daxin Pharmaceutical Co., Ltd.